{
    "clinical_study": {
        "@rank": "52111", 
        "arm_group": [
            {
                "arm_group_label": "Dose  I - 80 mg  PBF-509", 
                "arm_group_type": "Experimental", 
                "description": "one 80 mg PBF-509 capsule"
            }, 
            {
                "arm_group_label": "Dose I - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "one Placebo capsule"
            }, 
            {
                "arm_group_label": "Dose II - 160 mg PBF-509", 
                "arm_group_type": "Experimental", 
                "description": "Two 80 mg PBF-509 capsule"
            }, 
            {
                "arm_group_label": "Dose II - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Two Placebo capsule"
            }, 
            {
                "arm_group_label": "Dose III - 240 mg PBF-509", 
                "arm_group_type": "Experimental", 
                "description": "three 80 mg PBF-509 capsule"
            }, 
            {
                "arm_group_label": "Dose III - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Three Placebo capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to assess the safety and tolerability of three doses of PBF-509 (80 mg, 160 mg and 240\n      mg) after repeated (8 days) single daily oral dose administration in young male and female\n      healthy subjects."
        }, 
        "brief_title": "Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) \"After Multiple Oral Doses\" in Healthy Volunteers", 
        "condition": "Parkinson Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or females subjects, 18-45 years (inclusive) of age at the time of\n             enrollment.\n\n          -  Females must be of non-childbearing potential (i.e., surgically sterile) or have to\n             use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault\n             cap with spermicide. Males should agree to abstain from sexual intercourse with a\n             female partner or agree to use a condom/spermicide, in addition to having their\n             female partner use some contraceptive measures.\n\n          -  Clinically acceptable blood pressure and pulse rate in supine and standing position.\n             Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.\n\n          -  Body weight within normal range (Quetelet's index between 19 and 26) expressed as\n             weight (kg) / height (m2).\n\n          -  Able to understand the nature of the study and comply with all their requirements.\n\n          -  Free acceptance to participate in the study by obtains signed informed consent form\n             approved by the Ethics Committee of the Hospital (CEIC).\n\n        Exclusion Criteria:\n\n          -  History of serious adverse reactions or hypersensitivity to any drug.\n\n          -  Presence or history of allergies requiring acute or chronic treatment (except\n             seasonal allergic rhinitis).\n\n          -  Background or clinical evidence of chronic diseases.\n\n          -  Acute illness two weeks before drug administration.\n\n          -  Having undergone major surgery during the previous 6 months.\n\n          -  Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine\n             patches, etc., for 6 months prior to the administration of the study medication\n\n          -  History of alcohol dependence or drug abuse in the last 5 years or daily consumption\n             of alcohol > 40 g for men or 24 gr/day for women or high consumption of stimulating\n             beverages (> 5 coffees, teas or coca cola drinks/ day)\n\n          -  Abnormal physical findings of clinical significance at the screening examination or\n             baseline which would interfere with the objectives of the study.\n\n          -  Need of any prescription medication within 14 days prior to the administration of the\n              drug and non prescription medication or herbal medicines within 7 days prior to the\n             administration of the drug.\n\n          -  Participation in other clinical trials during the previous  90 days in which an\n             investigational drug or a commercially available drug was tested.\n\n          -  Having donated blood during 4 weeks period before inclusion in the study.\n\n          -  Existence of any surgical or medical condition which might interfere with the\n             absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or\n             hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms\n             of pronounced constipation or diarrhea or conditions associated with total or partial\n             obstruction of the urinary tract.\n\n          -  12 lead ECG obtained at screening with PR \u2265 220 msec, QRS \u2265 120 msec and QTc \u2265 440\n             msec, bradycardia (<50 bpm) or clinically significant minor ST wave changes or any\n             other abnormal changes on the screening ECG that would interfere with measurement of\n             the QT interval.\n\n          -  Symptoms of a significant somatic or mental illness in the four week period preceding\n             drug administration.\n\n          -  History of hepatitis HBV and / or HCV and / or positive serology results which\n             indicate the presence of hepatitis B surface antigen and / or detectable HCV\n             ribonucleic acid (RNA).\n\n          -  Positive results from the HIV serology.\n\n          -  Clinically significant abnormal laboratory values (as determined by the Principal\n             Investigator) at the screening evaluation.\n\n          -  Positive results of the drugs at screening period or the day before starting\n             treatment period. A minimum list of drugs that will be screened for include\n             Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive\n             results may be repeated at the discretion of the Principal Investigator).\n\n          -  Known hypersensitivity to the study drug or the composition of the galenical form.\n\n          -  History of psychiatric diseases or epileptic seizures\n\n          -  Females with positive results from the pregnancy test or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111330", 
            "org_study_id": "IIBSP-PBF-2013-155", 
            "secondary_id": "2013-005035-25"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose  I - 80 mg  PBF-509", 
                    "Dose II - 160 mg PBF-509", 
                    "Dose III - 240 mg PBF-509"
                ], 
                "intervention_name": "PBF-509", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose I - Placebo", 
                    "Dose II - Placebo", 
                    "Dose III - Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "email": "CDelgadoE@santpau.cat", 
                "last_name": "Claudia E. Delgado E, MD", 
                "phone": "(+34) 935 537 634"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08025"
                }, 
                "name": "CIM Sant Pau - I.I.B. Sant Pau"
            }, 
            "investigator": {
                "last_name": "Joan Martinez Colomer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "6", 
        "official_title": "Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) \"After Multiple Oral Doses\" in Healthy Volunteers", 
        "overall_contact": {
            "email": "cdelgadoe@santpau.cat", 
            "last_name": "Claudia E. Delgado, MD", 
            "phone": "0034935537634"
        }, 
        "overall_official": {
            "affiliation": "CIM Sant Pau - I.I.B. Sant Pau", 
            "last_name": "Juan Mart\u00ednez Colomer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "day 0-9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111330"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacokinetic Profile Analysis (Plasma concentrations)", 
            "safety_issue": "No", 
            "time_frame": "day 0-9"
        }, 
        "source": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
        "sponsors": {
            "collaborator": {
                "agency": "Palo Biofarma, S.L", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}